Cardinal Health (CAH) just unveiled an update.
Cardinal Health, Inc. has elected Robert W. Azelby to its Board of Directors effective March 1, 2024. Azelby, who brings experience as the former CEO of biotech company Eliem Therapeutics, will also serve on the Board’s Risk Oversight Committee. Recognized as independent according to NYSE and Exchange Act rules, he will receive the standard compensation for non-employee directors. His appointment is not based on any prior arrangements or pending transactions that require disclosure. The company publicly announced Azelby’s election in a recent news release.
For an in-depth examination of CAH stock, go to TipRanks’ Stock Analysis page.
